title: Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience.
abstract: Posttransplantation lymphoproliferative disorder (PTLD) is a serious complication following solid organ transplantation that has been linked to Epstein-Barr virus (EBV) infection. The aim of this article was to describe a single-center experience with the multiplicity of clinical presentations of PTLD. Among 350 liver transplantations performed in 303 children, 13 survivor children displayed a histological diagnosis of PTLD (13/242 survivors; 5.4%). The age at diagnosis ranged from 12 to 258 months (median, 47), and the time from transplantation ranged from 1 to 84 months (median, 13). Ten of these children (76.9%) were EBV-naïve prior to transplantation. Fever was present in all cases. The clinical signs at presentation were anemia (92.3%), diarrhea and vomiting (69.2%), recurrent upper airway infections (38.4%), Waldeyer ring lymphoid tissue hypertrophy (23.0%), abdominal mass lesions (30.7%), massive cervical and mediastinal adenopathy (15.3%), or gastrointestinal and respiratory symptoms (30.7%). One child developed fulminant hepatic allograft failure secondary to graft involvement by PTLD. Polymorphic PTLD was diagnosed in 6 patients; 7 had the diagnosis of lymphoma. Treatment consisted of stopping immunosuppression as well as starting intravenous gancyclovir and anti-CD20 monoclonal antibody therapy. The mortality rate was 53.8%. The clinical presentation of PTLD varied from fever of unknown origin to fulminant hepatic failure. The other symptoms that may be linked to the diagnosis of PTLD are pancytopenia, tonsil and adenoid hypertrophy, cervical or mediastinal lymph node enlargement, as well as abdominal masses. Despite numerous advances, the optimal treatment approach for PTLD is not completely known and the mortality rate is still high.
authors.affiliation: University of São Paulo Medical School, São Paulo, Brazil.
authors.forename: M L
authors.initials: ML
authors.lastname: Pinho-Apezzato
authors.forename: U
authors.initials: U
authors.lastname: Tannuri
authors.forename: A C A
authors.initials: AC
authors.lastname: Tannuri
authors.forename: E S
authors.initials: ES
authors.lastname: Mello
authors.forename: F
authors.initials: F
authors.lastname: Lima
authors.forename: N E
authors.initials: NE
authors.lastname: Gibelli
authors.forename: M M
authors.initials: MM
authors.lastname: Santos
authors.forename: A A
authors.initials: AA
authors.lastname: Ayoub
authors.forename: J G
authors.initials: JG
authors.lastname: Maksoud-Filho
authors.forename: M C
authors.initials: MC
authors.lastname: Velhote
authors.forename: M M
authors.initials: MM
authors.lastname: Silva
authors.forename: W C
authors.initials: WC
authors.lastname: Andrade
authors.forename: H T
authors.initials: HT
authors.lastname: Miyatani
mesh_terms: D001656:Biliary Atresia / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D003110:Colonic Neoplasms / Q000473:pathology; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D020031:Epstein-Barr Virus Infections / Q000453:epidemiology; D005260:Female; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D016031:Liver Transplantation / Q000009:adverse effects* / Q000276:immunology; D008198:Lymph Nodes / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000473:pathology; D008232:Lymphoproliferative Disorders / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology; D008297:Male; D011183:Postoperative Complications / Q000473:pathology*; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D017741:Survivors; D016559:Tacrolimus / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011241:Prednisone; D016559:Tacrolimus